UPDATE 1-Lilly beats forecasts, helped by cost controls
July 24, 2014 at 07:06 AM EDT
July 24 (Reuters) - Eli Lilly and Co's quarterly revenue plunged due to generic competition for its Cymbalta depression drug and its Evista osteoporosis treatment, but earnings beat forecasts, helped by cost controls.
